ArticleFrontiers in microbiology2025
Clinical and radiological characteristics of Mpox pneumonia in immunosuppressed HIV-infected patients: a multicenter study from China.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In people living with HIV, particularly with low CD4 Methods: This multicenter retrospective study analyzed 41 HIV-infected patients with Mpox (June 2022-February 2025), divided into a pneumonia group ( Results: All patients were men who have sex with men. Mpox pneumonia occurred almost exclusively in patients with CD4 Conclusion: Mpox pneumonia in HIV-infected individuals primarily affects those with advanced immunosuppression, presenting with disseminated necrotizing pulmonary nodules, multisystem involvement, and high mortality. Consistent ART markedly improves prognosis, highlighting the need for early identification of high-risk patients and integrated management-including sustained ART and targeted Mpox treatment-to reduce severe outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.